Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.
2.

Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life.

Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS.

Arch Neurol. 2000 Sep;57(9):1319-24.

PMID:
10987899
3.
5.

Evaluation of the Expanded Disability Status Scale and the Multiple Sclerosis Functional Composite as clinical endpoints in multiple sclerosis clinical trials: quantitative meta-analyses.

Bin Sawad A, Seoane-Vazquez E, Rodriguez-Monguio R, Turkistani F.

Curr Med Res Opin. 2016 Dec;32(12):1969-1974. Epub 2016 Sep 7.

PMID:
27603119
6.
7.

A study validating changes in the multiple sclerosis functional composite.

Hoogervorst EL, Kalkers NF, Uitdehaag BM, Polman CH.

Arch Neurol. 2002 Jan;59(1):113-6.

PMID:
11790238
8.

Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.

Kragt JJ, Thompson AJ, Montalban X, Tintoré M, Río J, Polman CH, Uitdehaag BM.

Neurology. 2008 Mar 25;70(13 Pt 2):1084-91. doi: 10.1212/01.wnl.0000288179.86056.e1. Epub 2008 Jan 9.

PMID:
18184917
9.

The multiple sclerosis functional composite: a clinically meaningful measure of disability.

Polman CH, Rudick RA.

Neurology. 2010 Apr 27;74 Suppl 3:S8-15. doi: 10.1212/WNL.0b013e3181dbb571. Review.

PMID:
20421572
10.

Assessing disability progression with the Multiple Sclerosis Functional Composite.

Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW.

Mult Scler. 2009 Aug;15(8):984-97. doi: 10.1177/1352458509106212.

PMID:
19667023
11.

Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.

Baier ML, Cutter GR, Rudick RA, Miller D, Cohen JA, Weinstock-Guttman B, Mass M, Balcer LJ.

Neurology. 2005 Mar 22;64(6):992-5.

PMID:
15781814
12.

The psychometric properties of clinical rating scales used in multiple sclerosis.

Sharrack B, Hughes RA, Soudain S, Dunn G.

Brain. 1999 Jan;122 ( Pt 1):141-59.

PMID:
10050902
13.

MS functional composite: relation to disease phenotype and disability strata.

Kalkers NF, de Groot V, Lazeron RH, Killestein J, Adèr HJ, Barkhof F, Lankhorst GJ, Polman CH.

Neurology. 2000 Mar 28;54(6):1233-9.

PMID:
10746590
14.

How similar are commonly combined criteria for EDSS progression in multiple sclerosis?

Kragt JJ, Nielsen IM, van der Linden FA, Uitdehaag BM, Polman CH.

Mult Scler. 2006 Dec;12(6):782-6.

PMID:
17263007
15.

[Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].

Mezei Z, Bereczki D, Csiba L, Csépány T.

Ideggyogy Sz. 2006 Nov 20;59(11-12):442-7. Hungarian.

PMID:
17203882
16.

The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials.

Rudick RA, Cutter G, Reingold S.

Mult Scler. 2002 Oct;8(5):359-65. Review.

PMID:
12356200
17.

Development of a multiple sclerosis functional composite as a clinical trial outcome measure.

Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW, Lublin F, Miller AE, Rao SM, Reingold S, Thompson A, Willoughby E.

Brain. 1999 May;122 ( Pt 5):871-82.

PMID:
10355672
18.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
19.

Comparison of patient-reported outcome measures in multiple sclerosis.

Schäffler N, Schönberg P, Stephan J, Stellmann JP, Gold SM, Heesen C.

Acta Neurol Scand. 2013 Aug;128(2):114-21. doi: 10.1111/ane.12083. Epub 2013 Feb 7.

PMID:
23398571
20.

Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.

Rudick RA, Cutter G, Baier M, Fisher E, Dougherty D, Weinstock-Guttman B, Mass MK, Miller D, Simonian NA.

Neurology. 2001 May 22;56(10):1324-30.

PMID:
11376182

Supplemental Content

Support Center